Related Experiment Video
Updated: Mar 13, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use
Michael Copland1, Paul Komenda2, Eric D Weinhandl3
1Division of Nephrology, University of British Columbia, Vancouver, Canada.
Insights
Intensive hemodialysis (HD), particularly nocturnal HD, effectively lowers high phosphorus levels in end-stage renal disease patients. This approach reduces the reliance on phosphate binders, improving patient management.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Mineral and Bone Disorders
Background:
- Mineral and bone disorder is a frequent complication in end-stage renal disease (ESRD).
- Hyperphosphatemia in ESRD patients contributes to cardiovascular complications, including calcification of the myocardium, valves, and arteries.
- Elevated serum phosphorus levels (≥5.0 mg/dL) are linked to increased cardiovascular mortality and morbidity.
Purpose of the Study:
- To evaluate the impact of intensive hemodialysis (HD) on serum phosphorus levels and the requirement for phosphate binders in ESRD patients.
- To compare the efficacy of daily and nocturnal HD schedules against conventional thrice-weekly HD.
Main Methods:
- Analysis of data from randomized clinical trials, including the Frequent Hemodialysis Network (FHN) trial.
- Comparison of serum phosphorus levels between patients undergoing intensive HD (daily or nocturnal) and standard thrice-weekly HD.
- Assessment of changes in phosphate binder dosage and discontinuation rates.
Main Results:
- Intensive HD, specifically nocturnal HD, significantly reduced serum phosphorus levels compared to conventional HD.
- Short daily HD lowered phosphorus by 0.6 mg/dL, while nocturnal HD lowered it by 1.6 mg/dL.
- Intensive HD decreased phosphate binder use, with 75% of nocturnal HD patients discontinuing binders.
Conclusions:
- Intensive HD, especially nocturnal HD, is an effective strategy for managing hyperphosphatemia in ESRD patients.
- This approach can significantly reduce the burden of phosphate binders, improving adherence and potentially reducing healthcare costs.
- Intensive HD demonstrates a clear benefit in phosphorus control without significant impact on calcium or parathyroid hormone levels.
Abstract:
Mineral and bone disorder is a common complication of end-stage renal disease. Notably, hyperphosphatemia likely promotes calcification of the myocardium, valves, and arteries. Hyperphosphatemia is associated with higher risk for cardiovascular mortality and morbidity along a gradient beginning at 5.0mg/dL. Among contemporary hemodialysis (HD) patients, mean serum phosphorus level is 5.2mg/dL, although 25% of patients have serum phosphorus levels of 5.5 to 6.9mg/dL; and 13%, >7.0mg/dL. Treatment of hyperphosphatemia is burdensome. Dialysis patients consume a mean of 19 pills per day, half of which are phosphate binders. Medicare Part D expenditures on binders for dialysis patients approached $700 million in 2013. Phosphorus removal with thrice-weekly HD (4 hours per session) is ∼3,000mg/wk. However, clearance is unlikely to counterbalance dietary intake, which varies around a mean of 7,000mg/wk. Dietary restriction and phosphate binders are important interventions, but each has limitations. Dietary control is complicated by limited access to healthy food choices and unclear labeling. Meanwhile, adherence to phosphate binders is poor, especially in younger patients and those with high pill burden. Multiple randomized clinical trials show that intensive HD reduces serum phosphorus levels. In the Frequent Hemodialysis Network (FHN) trial, short daily and nocturnal schedules reduced serum phosphorus levels by 0.6 and 1.6mg/dL, respectively, relative to 3 sessions per week. A similar effect of nocturnal HD was observed in an earlier trial. In the daily arm of the FHN trial, intensive HD significantly lowered estimated phosphate binder dose per day, whereas in the nocturnal arm, intensive HD led to binder discontinuation in 75% of patients. However, intensive HD appears to have no meaningful effects on serum calcium and parathyroid hormone concentrations. In conclusion, intensive HD, especially nocturnal HD, lowers serum phosphorus levels and decreases the need for phosphate binders.
More Related Videos
14:55Analysis of Minerals Produced by hFOB 1.19 and Saos-2 Cells Using Transmission Electron Microscopy with Energy Dispersive X-ray Microanalysis
Published on: June 24, 2018
07:11Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Related Concept Videos
Hemodialysis III: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Peritoneal Dialysis III: Nursing Management
Hemodialysis II: Procedure and Complications
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily...
Hemodialysis I: Introduction